Status:
UNKNOWN
Galectin-3 for Thromboembolic Formation in Patients With Atrial Fibrillation CHA₂DS₂-VASc Scoring
Lead Sponsor:
Assiut University
Conditions:
Atrial Fibrillation
Stroke
Eligibility:
All Genders
18+ years
Brief Summary
Atrial Fibrillation is considered as one of a common cardiac arrhythmia that presented with rapid and irregular rhythm and has an increased incidence.There are different types of atrial fibrillation o...
Detailed Description
In 2001, the CHADS₂ score (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke) was developed to predict the risk of stroke in patients with non rheumatic atrial fibrillat...
Eligibility Criteria
Inclusion
- Gender: men and women.
- Age \>18 years.
- Diagnosed as non valvular atrial fibrillation patients either paroxysmal or persistent types.
Exclusion
- pregnancy
- valvular heart diseases.
- Congenital heart diseases.
- Heart failure.
- Ischemic heart disease.
- Inflammatory diseases.
- Cancer.
- Thyroid disease.
Key Trial Info
Start Date :
June 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT03413072
Start Date
June 1 2018
End Date
June 1 2020
Last Update
January 29 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.